Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 62135-999

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 62135-999). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Rizatriptan Tabs 10mg Bottle Label)

Label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10 mg, containing 18 tablets. The label states phenylketonurics contain 314 mg phenylalanine per tablet. It is Rx only and manufactured by Chartwell RX, LLC. Storage and usage instructions including usual dosage and temperature are listed alongside a barcode.*

FDA Label Image

"image Description" (Rizatriptan Tabs 5mg Bottle Label)

Label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 5 mg strength, in a package containing 18 tablets. The label indicates Rx Only status and specifies Chartwell RX as the labeler. The label includes phenylketonurics warning, storage instructions, patient dispensing information, and a barcode.*

FDA Label Image

"image Description" (Rizatriptan Tabs Graph 1)

A line graph depicting the estimated probability of response over 2 hours post-dose for Rizatriptan Benzoate tablets at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose, and the y-axis shows the estimated probability of response in percentage, with Rizatriptan showing higher response rates than placebo over time.*

FDA Label Image

"image Description" (Rizatriptan Tabs Graph 2)

Line graph comparing the estimated probability of medication rescue over 24 hours post-dose for Rizatriptan Benzoate 5 mg tablets, 10 mg tablets, and placebo. The x-axis represents hours post-dose, while the y-axis shows estimated probability on the left and an additional percentage scale on the right. The 10 mg dosage shows the highest probability, followed by 5 mg, with placebo the lowest throughout the period.*

FDA Label Image

"image Description" (Rizatriptan Tabs Graph 3)

A line graph depicting the estimated probability of response over time (hours post-dose) for Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph shows increasing response probabilities within 2 hours post-dose for both drug strengths, with 10 mg having higher response rates than 5 mg and placebo.*

FDA Label Image

"image Description" (Rizatriptan Tabs Graph 4)

A line graph showing the estimated probability of remediation or relief over 24 hours post-dose for Rizatriptan Benzoate Orally Disintegrating Tablets at 5 mg and 10 mg doses compared to placebo. The graph plots time in hours on the x-axis against the estimated probability on the y-axis, illustrating the comparative effects of two strengths and placebo over time.*

FDA Label Image

"image Description" (Rizatriptan Tabs Graph 5)

A line graph comparing the effects of MAXALT-MLT versus Placebo over time. The x-axis represents hours post Stage 2 dose, ranging from 0.5 to 2 hours, and the y-axis shows percent values with 95% confidence intervals up to 100%. The graph illustrates an increasing trend in percent response for both treatments over time.*

FDA Label Image

"image Description" (Rizatriptan Tabs Structure)

Chemical structure of Rizatriptan Benzoate, showing the molecular arrangement with a triazole and indole ring system, an extended aliphatic chain with a dimethylamino group, and a benzoic acid moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.